With global rights to TTP's soft-mist inhalation platform, Lupin gets access to the drug delivery system used by Boehringer Ingelheim for Spiriva Respimat and it will be interesting to watch pricing as Lupin leverages the aerosolization technology across respiratory products. Meanwhile, the company has entered a partnership with Biomm for marketing its Neulasta biosimilar in Brazil.
Lupin Limited’s recent deal with TTP Plc for its soft-mist inhalation technology platform is expected to provide a leg-up to the Indian firm's respiratory ambitions.
Recently, Lupin Inc
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The gene-editing company is making a deal with RNA interference-focused Sirius, but still focusing on cardiovascular disease, a major area of its pipeline.
The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.
Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.
The German biotech has been forced into insolvency and NASDAQ suspension.
The German biotech has been forced into insolvency and NASDAQ suspension.
Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.
Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.
